AccuStem Sciences, Inc. is a clinical stage diagnostics company, which engages in medical practice activities. It also focuses on commercialization of a proprietary genomic test, StemPrintER, for patients with early-stage breast cancer. The company was founded by Gabriele Marco Antonio Cerrone on June 5, 2020 and is headquartered in New York, NY.